PIK3CA mutations have been associated with a better disease-free survival (DFS) in early hormone receptor positive (HR+)/HER2-negative (HER2-) BC [4], while PIK3CA mutant HR+/HER2- metastatic BC (mBC) showed resistance to chemotherapy and poorer outcomes [5]. This evidence concerns the gene ERBB2 and breast cancer.